FOXO4-DRI: What It Is, Where to Get It Prescribed, and What It Costs

FOXO4-DRI is not a fragment of something the body makes. It was designed in the laboratory of Peter de Keizer at Erasmus University Medical Center in Rotterdam and described in a 2017 paper in Cell (Baar and colleagues). The starting point was FOXO4, a transcription factor that senescent cells use to stay alive: in those cells FOXO4 holds onto p53 in the nucleus and keeps it from triggering the cell's own death programme. The peptide copies a stretch of FOXO4 and acts as a decoy, occupying p53 so the real FOXO4 cannot.

"Senescent" needs a definition, because everything on this page depends on it. A senescent cell is one that has stopped dividing permanently, usually after damage or too many divisions, but has not died. It sits in tissue and secretes inflammatory signals, a pattern called the senescence-associated secretory phenotype. The senolytic hypothesis is that removing these cells improves the tissue around them. FOXO4-DRI is one of the compounds designed to test that hypothesis.

DRI stands for D-retro-inverso. Ordinary peptides are built from L-amino acids and are chewed up by proteases within minutes. A retro-inverso peptide is built from the mirror-image D-amino acids, assembled in reverse order, so the side chains end up in roughly the same spatial arrangement as the original sequence while the backbone is one that proteases do not recognise. The practical result is a peptide that survives far longer in the body than the natural sequence would. FOXO4-DRI also carries a short cell-penetrating tail borrowed from the HIV TAT protein, which is what lets it cross the cell membrane and reach p53 in the nucleus.

So the name is a description of the chemistry: the FOXO4 sequence, made backwards out of D-amino acids, with a delivery tag attached.

It is not a hormone and it does not act on a hormone receptor. It is not a growth hormone secretagogue like ipamorelin or sermorelin, and it does not change IGF-1. It is not an antioxidant, it is not a mitochondrial peptide like MOTS-c or SS-31, and it is not a recovery peptide like BPC-157. It does not repair cells. Its entire described action is to remove a particular category of cell, and it has no described action on healthy dividing cells at all.

It is also not a proven anti-aging treatment. It is an experimental senolytic with a small body of animal and cell research behind it, described in more detail below.

In the 2017 Cell paper, the de Keizer group reports that FOXO4 is expressed at high levels in senescent cells and that it binds p53 there. p53 is the protein that normally decides whether a damaged cell dies; a senescent cell has damage but does not die, and the paper identifies the FOXO4–p53 complex as one reason why. FOXO4-DRI is described as competing for that interaction. When it binds p53, FOXO4 cannot, and the arrangement that was keeping the cell alive is disrupted.

A 2025 paper in Nature Communications from the same collaborators (Bourgeois and colleagues) solved NMR structural models of the interaction and reports that FOXO4-DRI binds the disordered transactivation domain of p53, the same region the natural FOXO4 forkhead domain uses. That is structural confirmation of the target the original paper proposed.

Once the complex is disrupted, the Cell paper describes p53 leaving the nucleus of the senescent cell and moving to the cytoplasm, where it triggers the cell's own apoptosis programme. Later cell work has filled in the downstream steps: a 2026 paper in Frontiers in Bioengineering and Biotechnology on senescent endothelial cells describes phosphorylated p53 being exported from the nucleus, followed by BAX and cleaved caspase-3, the standard machinery of programmed cell death. A 2025 paper in Communications Biology on keloid fibroblasts describes the same nuclear exclusion of p53 phosphorylated at serine 15.

The phrase "cell-intrinsic" matters. The cell is described as killing itself through its own normal pathway, rather than being destroyed from outside. That is why the proposed action is selective: a cell that is not senescent has no FOXO4–p53 complex to disrupt.

The central claim of the senolytic field is that a compound kills senescent cells and leaves healthy ones alone. For FOXO4-DRI, the 2017 Cell paper reports that the peptide induced apoptosis in senescent cells but not in proliferating cells in culture, and that it was tolerated in mice at the doses used. A 2021 study in Frontiers in Bioengineering and Biotechnology on human chondrocytes expanded in a dish reports that the peptide selectively removed the senescent fraction while sparing the rest. That is the basis for describing it as selective, and it is a cell-culture and mouse observation, not a human one.

Senescent cells are not a problem only because they take up space. The secretory phenotype, a mix of cytokines, proteases and growth factors, is what the field considers most damaging to surrounding tissue. Mouse work on aged Leydig cells (Experimental Gerontology, 2024) describes FOXO4-DRI reducing the secretion of these factors after senescent cells were cleared, with a knock-on effect on neighbouring cells in co-culture. The logic is that removing the source removes the signal. Again, this is a description from animal and cell models.

The first thing the 2017 Cell paper tested was doxorubicin, a chemotherapy drug that induces senescence and causes side effects partly through it. The paper reports that FOXO4-DRI neutralised doxorubicin-induced chemotoxicity in mice, measured by liver toxicity markers and physical wellbeing, under conditions where the peptide itself was well tolerated. This is the cleanest experiment in the literature because senescence was induced deliberately and the comparison is direct.

The same paper then treated two kinds of aged mice: a progeroid strain that ages rapidly because of a DNA repair defect, and ordinary mice that were simply old. In both, the authors report restored fitness (running-wheel activity), fur density, and renal function, the last measured as a reduction in urinary albumin. Treatment was a short course of intermittent intraperitoneal injection, not daily subcutaneous dosing, which is worth keeping in mind when reading the directions on this page. These are the findings that made the compound famous, and they are mouse findings.

A group in China has published two studies on the aging male reproductive system. The first, in Aging in 2020, reports that FOXO4 is expressed in human Leydig cells, that its nuclear localisation in elderly men correlated with lower testosterone synthesis, and that in aged mice FOXO4-DRI cleared senescent Leydig cells and was associated with improved testosterone secretion. The second, in Experimental Gerontology in 2024, reports improved sperm quality and spermatogenesis in naturally aged mice after treatment, with reduced secretory-phenotype output from Leydig cells. The human component of the first study was observational tissue analysis, not treatment of people.

A 2023 paper in Naunyn-Schmiedeberg's Archives of Pharmacology reports that in a bleomycin-induced pulmonary fibrosis model in mice, FOXO4-DRI was associated with milder pathological change and less collagen deposition, and describes the peptide reducing extracellular matrix production in activated fibroblasts. The 2025 Communications Biology keloid paper describes senescent fibroblasts in human keloid tissue and reports that FOXO4-DRI induced their apoptosis in keloid organ cultures and cell models. The keloid tissue was human, but it was studied in a dish after removal, which is a different thing from treating a person.

The 2026 Frontiers in Bioengineering and Biotechnology paper reports that injection of FOXO4-DRI in both naturally aged and induced-aging mice was associated with reduced aortic aging markers and improved aortic function, and describes the p53 pathway mechanism in oxygen-glucose-deprived endothelial cells. This is the most recent addition to the animal literature.

Two studies have used human cells directly: the 2021 chondrocyte paper (cells expanded for autologous cartilage implantation, where senescence accumulates during expansion) and the 2025 keloid paper. Both report selective removal of senescent cells in culture. Cell-culture work on human cells is a step above mouse work in relevance, but it is not evidence of what happens when the peptide is injected into a person.

There are no randomised human trials of FOXO4-DRI. There are no published non-randomised human trials either. No dose-finding study, no pharmacokinetic study, no safety study in people has been published. The compound was first described in 2017, and as of September 2026 the human evidence base consists of observational tissue analysis (the Leydig cell study looked at FOXO4 localisation in tissue from elderly men) and human cells studied outside the body.

This makes FOXO4-DRI different from most of the peptides on this site. BPC-157 has decades of animal work plus early-phase human studies for gut indications; semaglutide has large trials. FOXO4-DRI has neither. The honest framing is: a well-defined mechanism, a small number of mouse and cell studies that are consistent with each other, and no human data. Anyone describing it as proven, or citing human results, is describing something that does not exist.

• It does not establish that FOXO4-DRI clears senescent cells in humans. Every senolytic observation is from mice or cultured cells.
• It does not establish any effect on human aging, lifespan, healthspan, appearance, energy, or any other outcome a person might hope for.
• It does not establish a dose, a schedule, or a route for humans. The mouse work used intermittent intraperitoneal injection over days, not weeks of subcutaneous dosing.
• It does not establish safety in humans, short-term or long-term. The mouse studies report the peptide was tolerated; that is the extent of it.
• It does not establish what happens with repeated courses. Whether senescent cells re-accumulate, and on what timeline, has not been studied in people.
• It does not establish anything about the compounded product specifically. The published work used research-grade peptide in a laboratory setting.

Senescent cell clearance, if it happens, is not something you would feel. There is no described acute effect; the peptide is not a stimulant, not a sedative, not an anti-inflammatory in the direct sense. Most people should expect to notice nothing during a first vial, and that is consistent with the mechanism rather than a sign of failure. What is more likely to be noticeable early is the injection site.

In the 2017 Cell paper, effects in aged mice were measured over days to a few weeks after a short course. A mouse ages in two years and its tissues turn over quickly. There is no established conversion to human timescales, and prescribers who use FOXO4-DRI generally treat it as an intermittent course rather than a continuous daily medication, which is why the directions are five days a week and a vial is sized at about four weeks.

For a recovery peptide, a sore tendon feeling better is a reasonable marker. For a senolytic there is no comparable signal a patient can observe. Some prescribers look at inflammatory markers on bloodwork before and after; whether that is meaningful for this compound has not been studied. Set expectations around the honest position: this is an experimental compound with a defined mechanism, not a treatment with an expected result.

There is no withdrawal and no rebound described in the animal work. Whether any senescent cells removed would re-accumulate, and how fast, is unknown in humans. Whether a repeat course is appropriate is a physician's decision, and the answer may reasonably be no.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. At 2 mg/mL, that volume contains 0.5 mg of FOXO4-DRI. You are not calculating anything; the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. The directions are Monday through Friday with the weekend off, which reflects how prescribers have chosen to structure an intermittent course rather than anything established by research. The published mouse work used intraperitoneal injection, which is not a route used in people for this purpose; the subcutaneous route is a clinical decision, not a translated one.

20 doses at five per week is four weeks, which is why refills run on a 28-day cycle. One vial per fill, always. Whether a second vial is prescribed at all is a separate physician decision each time, and with an experimental compound it is reasonable for that answer to change.

Refrigerated, and it ships that way in insulated packaging with ice packs. The D-amino acid chemistry makes the peptide more stable than a natural sequence, but the compounded solution is still handled as a refrigerated multi-dose vial. Beyond-use dating runs from first puncture and is on the label.

Both are filed under anti-aging and the similarity ends there. Epithalon is a four-amino-acid peptide derived from pineal gland extracts, and its research is largely older Russian work on telomerase and pineal function. FOXO4-DRI is a designed D-peptide with a single defined molecular target. Epithalon was reviewed by the FDA's advisory committee in July 2026; FOXO4-DRI has not been nominated. A physician choosing between them is choosing between two different hypotheses about aging, neither of which has randomised human trial support.

NAD+ is a coenzyme the body makes, involved in cellular energy metabolism and DNA repair, and it has been given to humans in clinical studies. It does not kill any cells. FOXO4-DRI does nothing for energy metabolism directly and has no human studies. If a person wants one anti-aging intervention with human data, NAD+ is the more defensible choice; if a physician specifically wants to trial a senolytic, FOXO4-DRI is the only one in this catalogue.

MOTS-c and SS-31 act on mitochondria: MOTS-c is a mitochondrial-derived peptide described around metabolic signalling, and SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane. Both aim to improve how existing cells function. FOXO4-DRI aims to remove cells that no longer function. They are not alternatives so much as answers to different questions, and a physician may consider them in different people for different reasons.